Archived article
Please note that tax, investment, pension and ISA rules can change and the information and any views contained in this article may now be inaccurate.
UK stocks were roughly flat Wednesday, but remained close to record highs following strong opening day of 2022 on Tuesday. At 08:57, the benchmark FTSE 100 index was up 1 points, or 0.02%, to 7,506.25.
Pharmaceutical company AstraZeneca was flat at £84.91 after completing the transfer of its global rights for pulmonary drugs Eklira and Duaklir to Covis Pharma for $270 million.
Home-testing healthcare company MyHealthChecked rallied 7% to 2.52 pence after signing a contract with AAH Pharmaceuticals for the supply of the Fit to Fly/Pre-departure rapid antigen test.
Specialty pharmaceutical company Shield Therapeutics gained 2% to 48.05 pence after entering into an exclusive licence agreement for Accrufer with KYE Pharmaceuticals in Canada.
Life sciences business OptiBiotix Health added 0.7% to 46.80 GBX after achieving British Retail Consortium accreditation. The accreditation paved the way for the company to sell final product solutions to partners in the retail channel containing its science backed pro and prebiotic ingredients.
Telecommunications and mobile money services company Airtel Africa fell 2% to 138.30 pence after announcing the first closing of the transaction to sell its telecommunications tower assets in Tanzania to a joint venture company owned by a subsidiary of SBA Communications Corporation, and Paradigm Infrastructure.
Gene and cell therapy group Oxford Biomedica rose 0.5% to £12.16 after signing a new license and supply agreement with Cabaletta Bio, granting the latter with a license to the company's LentiVector platform.
Cordiant Digital Infrastructure slipped 4.2% to 108.78 pence after entering into binding agreements to acquire a strategic interconnect data centre in New York and a digital infrastructure platform in Poland.
Life science company ValiRx fell 16.7% to 31.67 pence after entering into a service agreement with TheoremRx to engage with clinical research organisations and support vendors for the next clinical trial of the company's prostate cancer drug VAL201.